2023years10month23day, United States Patent and Trademark Office (USPTO) Office of the Chief Economist (OCE) A report was issued, Introduced in detailUSPTOTrends in patent applications related to COVID-19 diagnostic technologies. OCEdiscover, in2020After the emergence of the new coronavirus earlier this year, There has been a surge in patent-filing activity, Much of that growth was driven by small businesses and research institutions. The report found further evidence of that, Federal funding has had a significant impact in driving innovation in COVID-19 diagnostics among small R&D entities.

64%More than half of business applications for COVID-19 diagnosis come from small entities

On the basis ofOCEThe report of, 2021Year control4Quarterly totals were announced167A US patent application for a diagnostic technique for COVID-19. This isOCEThe keyword search method accounts for the number of US patent applications found20%, This is also the peak quarter for the publication of patent applications for COVID-19 diagnosis since the start of the pandemic. Although patent applications for COVID-19 diagnosis only account for all patent applications in the field of medical diagnosis1. 4%, But it accounts for all of the patent-filing activity related to COVID-1930%.

On the whole, OCEThe report was confirmed824A US patent application covering the diagnosis of COVID-19, The application time is2019years12Lunar solstice2023years4month. Enterprise applications accounted for all applications58%, And in all applications submitted by enterprise R&D applicants, 64%It was submitted by a business that qualified as a small entity. collegiate, Research institutions and hospitals accounted for all applications for COVID-19 diagnosis27%, There are in the group82%Patent applications are also filed by small entities. OCEThe report states that, "Perhaps surprisingly" In the patent application for COVID-19 diagnosis identified in the investigation, Applications from independent individuals accounted for13%.

The main contribution of small and micro entities to COVID-19 diagnostic innovation is also in line with larger trends "Run counter to" , But it also highlights the importance of small businesses in the development of COVID-19 diagnostics. OCEThe report states that, in2022Of all U. S. patents issued during that year, only24%A business that qualifies for a small or micro entity discount. On the contrary, In all applicant groups except government agencies, Small entities filed the largest number of patent applications for COVID-19 diagnostics.

Federal funding has helped promote small entity patent applications

Although inOCEConfirmed application for COVID-19 diagnosis, Government agencies only15item, But the report assesses the government's claims of interest in patent applications (interest statements) , It can be seen, Federal funding has contributed significantly to the development of the field. OCEBe found with88A patent application (Accounts for all applications for COVID-19 diagnosis10. 7%) Includes such statements showing the contribution of federal funds to the underlying invention. Small and micro entity applications account for the total number of applications81%, This not only shows "Baidu act" The federal funding mechanism in the United States has had a huge impact on COVID-19 research and development, It also illustrates how small businesses have been so far "Baidu act" The biggest beneficiary of the impact on innovation during the COVID-19 pandemic.

Through the analysis of cooperative patent classification (CPC) Subclass code, OCEThe report found that, In all applications for COVID-19 diagnosis, Nearly half are classified as analyzing materials through chemical and physical properties. In addition to measuring enzymes, Nucleic acids and microbes outside, exceed20%There are no other patent applications related to COVID-19 diagnosisCPCSubclass code. OCEThe report states that, Healthcare informatics performed better than expected, theCPCThe subclass code appears in12. 4%In the application for COVID-19 diagnosis. The report also states that, The figure partly reflects the impact of home-based diagnostic tests that have become popular during the coronavirus pandemic.

OCEThe report also reflects this fact, The invention of COVID-19 diagnostics is not always separate and distinct from COVID-19 vaccines and treatments. Such as, 8. 6%The application for public disclosure of COVID-19 diagnosis belongs toCPCA subclass of a compound or drug preparation with a specific therapeutic activity.

By analysis from "Deventer World Patent Index (Derwent World Patent Index) " International patent application data obtained in, OCEThe report found that, State Intellectual Property Office of China (CNIPA) The largest number of patents related to COVID-19 diagnosis were filed. During the COVID-19 pandemic, CNIPAThere are2643One patent in the same family relates to a novel coronavirus diagnostic technology, Well ahead of the United States Patent and Trademark Office in second place (USPTO) admissible784A patent of this kind. On the basis of "Patent cooperation treaty" (PCT) International applications submitted account forOCEThe investigation tracked the application of COVID-19 diagnosis35%, On account ofPCTSpecified from the priority date30National phase within months, Applicants can choose from more countries to apply during this period, That number is expected to continue to rise. (Be compiled fromipwatchdog. com)

TRANSLATORS: Wang Dan　proofread: Rason group



　　disclaimer: This network reprint or compile the original articles are from the network, Does not represent the views of this website or confirm the authenticity of its content. If the source is mislabeled or the copyright of the article is involved, Please contact us, This website will be corrected in due course, delete, thank you.